No profile data available.
DexCom, Inc. (DXCM) is a healthcare company in the chemical laboratory testing equipment industry, based in San Diego, United States, with about 11,000 full-time employees.
It reported revenue of $4.66 billion for fiscal year 2025, up 15.6% from fiscal year 2024, and net income of $836.30 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $1.31 billion, up 13.1% from a year before. United States was its largest region in fiscal year 2025, with 72% of revenue. Its market capitalization was $31.74 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally.
DexCom reported $4.66 billion in revenue for fiscal year 2025, up 15.6% from $4.03 billion in fiscal year 2024. In Q2 2026 revenue was $1.31 billion.
United States: 72% of revenue by region in fiscal year 2025, followed by International (28%).
$31.74 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (chemical laboratory testing equipment) include Senseonics Holdings, Inc. (SENS), OraSure Technologies, Inc. (OSUR), Anbio Biotechnology (NNNN), DarioHealth Corp. (DRIO).